Public Interest Patent Law Institute

Ensuring the patent system promotes innovation and access for all.

[Public Interest Patent Law Institute @PublicPatent]

TOMORROW - Nov 6th! Don’t miss our Patent Eligibility Webinar. Join leading experts as they explore how patent law influences access to care, research, and innovation.

TIME: 10am PT / 1pm ET
Register here: https://t.co/7WvbpXf5WB

#PatentLaw #PublicInterest #Innovation

[Public Interest Patent Law Institute @PublicPatent]

Join us for our Patent Eligibility Webinar on Thurs. Nov 6th! Expert panelists will discuss how patent law shapes access to care, research, and innovation.

🗓️ Thursday, Nov 6, 2025 at 10:00am PT / 1pm ET
🔗 Register here: https://t.co/7WvbpXf5WB

#PatentLaw #PublicInterest

[Public Interest Patent Law Institute @PublicPatent]

PIPLI — with the pro bono leadership of Kathi Vidal — has filed an amicus brief challenging a USPTO rule that shields aging patents from review. When old, invalid patents are protected, innovation and public access suffer. Read more: https://t.co/G4T5EuGdA8 #PublicInterest

[Public Interest Patent Law Institute @PublicPatent]

Our PERA blog post is live! We outline how PERA could dismantle Section 101 and the path forward for patents. The blog includes a letter our coalition has written to the Senate Judiciary Committee urging them to reject PERA and protect innovation! https://t.co/dSRkA2hvRQ

[Public Interest Patent Law Institute @PublicPatent]

Check out our new blog post! Don't Let Bad Patents Strangle AI in Its Crib - A look into open competition and how it applies to the world of AI innovation. https://t.co/yT8bmQf3hM

[Public Interest Patent Law Institute @PublicPatent]

VOTING is OPEN for our panel at #SXSW2026!

If selected, PIPLI's Alex Moss will join moderator Priya Nair @actonline and other guest speakers in this important discussion about SEPs and their impact on funding, licensing, and innovation.

Vote till 8/24!!

https://t.co/ZhEY5FQqfg

[Public Interest Patent Law Institute @PublicPatent]

VOTE for PIPLI at SXSW!

If selected, this panel will explore core issues surrounding standard-essential patents and how to move through the funding and licensing landmines of SEPs. PIPLI's Alex Moss will join as a guest speaker! VOTE now through Aug 24!
https://t.co/lMGXy6kiPd

[Public Interest Patent Law Institute @PublicPatent]

Patent Quality Week is back June 26 - July 3! With changes underway in the
U.S. patent system, now is the time to learn why patent quality over quantity matters across
the innovation ecosystem. Join the conversation: https://t.co/zxX4jT8no6

[Public Interest Patent Law Institute @PublicPatent]

Who really wins when courts decide if patents are valid instead of the USPTO? Law firms. More from @alexhmoss here: https://t.co/h6ytPDhoLn

[Public Interest Patent Law Institute @PublicPatent]

Pretty good patent news! It shouldn't take this much work to cut a flawed patent down to harmless size, but @mccoysm and @tobbelobb are heroes for doing it.

Big congrats and big thanks. 👏🏆🦸

[McCoy Smith @McCoySmith]

Posting below by a client who hired me to challenge a patent on a community's open source (GPL) 3D printing device.
Shows how often the most expensive alternative is suggested, or people are told not to even try.
H/T referral from Alex Moss @PublicPatent.
https://t.co/UlsP5Kp8ZQ

[Public Interest Patent Law Institute @PublicPatent]

Another day, another effort to protect invalid patents so that big pharma and foreign patent trolls can make bigger profits off American workers, patients, and consumers.

https://t.co/8VbOKkIGTA

[Public Interest Patent Law Institute @PublicPatent]

Many aspects of patent law are unclear and confusing. But patent eligibility isn't one of them.

One sign eligibility law crystal clear?

The fact that big pharma keeps asking Congress to re-write it in their favor instead of asking courts.

https://t.co/nGrNEZQWoW

[Public Interest Patent Law Institute @PublicPatent]

Together, we can protect the public's right to challenge invalid patents that harm countless Americans each year, especially those who depend on heavily patented drugs and medical devices.

To submit comments: https://t.co/gSMkVEBbsO

For more info: https://t.co/17AahaibcU

[Public Interest Patent Law Institute @PublicPatent]

@USPTO wants to restrict our ability to challenge invalid patents that drive up drug prices. Together, we can prevent that from happening.

To do that, we need to tell Patent Office to protect the public instead of big pharma.

https://t.co/17AahaibcU

[Public Interest Patent Law Institute @PublicPatent]

Want to learn how the patent system drives up drug prices and what you can do about it?

Join the conversation with @waxmanstrategies, @IMAKglobal, & us this Wednesday at 2pm ET.

More info below and registration here: https://t.co/fgVAI8YfGK

[Public Interest Patent Law Institute @PublicPatent]

At a recent House oversight hearing, USPTO Director Kathi Vidal said proposals restricting the public's ability to challenge invalid patents came from unnamed "stakeholders."

So we filed a FOIA request to find out who's telling the USPTO what to do.

https://t.co/598oon96pG

[Public Interest Patent Law Institute @PublicPatent]

More here on why we need Congress to get the USPTO to start executing the law instead of undermining it: https://t.co/lqEaagannp

[Public Interest Patent Law Institute @PublicPatent]

We're calling on Congress to protect our ability to challenge invalid patents that thwart competition, spike prices, and spur litigation -- with @uspirg , @Public_Citizen, @RSI @t1international, @MichiganUnited, & Public Innovation Project.
Our letter: https://t.co/7N95mv9vnw

[Public Interest Patent Law Institute @PublicPatent]

Given the one-sided hearing that happened this week, PIRG's report on patent abuse and drug pricing is more important than ever: https://t.co/ePhlMCAMPD

[Public Interest Patent Law Institute @PublicPatent]

Good news doesn't come all that often, but the European Commission's leaked regulations for licensing standard-essential patents suggests good news is combing for licensors, licensees, and consumers (but maybe not for lawyers).
https://t.co/RF0NNDnT3o